140 related articles for article (PubMed ID: 35857060)
1. Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment.
Mita T; Katakami N; Takahara M; Kawashima M; Wada F; Akiyama H; Morita N; Kidani Y; Yajima T; Shimomura I; Watada H
J Clin Endocrinol Metab; 2022 Aug; 107(9):2424-2432. PubMed ID: 35857060
[TBL] [Abstract][Full Text] [Related]
2. What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries.
Boels AM; Vos RC; Hermans TGT; Zuithoff NPA; Müller N; Khunti K; Rutten GEHM;
BMJ Open; 2017 Jul; 7(7):e016180. PubMed ID: 28701411
[TBL] [Abstract][Full Text] [Related]
3. Essential parameters and risk factors of the patients for diabetes care and treatment.
Bener A; Keskin FE; Kurtulus EM; Guzel M; Çekirdekçi EI; Kadıoğlu P; Konukoğlu D; Öztürk M
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S315-S320. PubMed ID: 28285988
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with treatment satisfaction in patients with type 2 diabetes mellitus using oral glucose-lowering agents: a cross-sectional study in urban districts in Japan.
Hayashi I; Watanabe N; Nakata S; Komatsu R; Motoda S; Fujita Y; Ishibashi C; Yamaguchi Baden M; Kimura T; Takahara M; Kozawa J; Imagawa A; Iwahashi H; Shimomura I
Endocr J; 2018 Oct; 65(10):1001-1009. PubMed ID: 30033945
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist led intervention towards management of type 2 diabetes mellitus and assessment of patient satisfaction of care - A prospective, randomized controlled study.
Simon MA; Raja BY; Varughese PC; Daniel LM; Sowjanya K; S KJ; S S; Rathinam KK; Kumar J P
Diabetes Metab Syndr; 2021; 15(5):102208. PubMed ID: 34298274
[TBL] [Abstract][Full Text] [Related]
6. [Factors associated with dissatisfaction with pharmacological treatment in patients with type 2 diabetes mellitus: A cross-sectional study].
Martínez-Perez P; Orozco-Beltrán D; Pomares-Gómez F; Gil-Guillén VF; Quesada JA; López-Pineda A; Nouni-García R; Carratalá-Munuera C
J Healthc Qual Res; 2023; 38(2):120-127. PubMed ID: 35933321
[TBL] [Abstract][Full Text] [Related]
7. A prospective cross-sectional study on quality of life and treatment satisfaction in type 2 diabetic patients with retinopathy without other major late diabetic complications.
Alcubierre N; Rubinat E; Traveset A; Martinez-Alonso M; Hernandez M; Jurjo C; Mauricio D
Health Qual Life Outcomes; 2014 Aug; 12():131. PubMed ID: 25138117
[TBL] [Abstract][Full Text] [Related]
8. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.
Genovese S; Tedeschi D
Adv Ther; 2013 Feb; 30(2):152-64. PubMed ID: 23430354
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy.
Lapolla A; Genovese S; Giorgino F; Disoteo O; Sartore G; Bartezaghi M; Del Prato S
Curr Med Res Opin; 2020 Apr; 36(4):555-562. PubMed ID: 31868033
[No Abstract] [Full Text] [Related]
10. Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus.
Ito H; Abe M; Antoku S; Omoto T; Shinozaki M; Nishio S; Mifune M; Togane M
Drug Des Devel Ther; 2014; 8():391-6. PubMed ID: 24790413
[TBL] [Abstract][Full Text] [Related]
11. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study.
Bech P; Moses R; Gomis R
Qual Life Res; 2003 Jun; 12(4):413-25. PubMed ID: 12797714
[TBL] [Abstract][Full Text] [Related]
12. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.
Secnik Boye K; Matza LS; Oglesby A; Malley K; Kim S; Hayes RP; Brodows R
Health Qual Life Outcomes; 2006 Oct; 4():80. PubMed ID: 17034640
[TBL] [Abstract][Full Text] [Related]
14. Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue.
Howorka K; Pumprla J; Schlusche C; Wagner-Nosiska D; Schabmann A; Bradley C
Qual Life Res; 2000; 9(8):915-30. PubMed ID: 11284211
[TBL] [Abstract][Full Text] [Related]
15. The Beneficial Effect of the Mobile Application
Chatzakis C; Floros D; Papagianni M; Tsiroukidou K; Kosta K; Vamvakis A; Koletsos N; Hatziagorou E; Tsanakas I; Mastorakos G
Diabetes Technol Ther; 2019 Nov; 21(11):627-634. PubMed ID: 31335204
[No Abstract] [Full Text] [Related]
16. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER.
Takahara M; Mita T; Katakami N; Wada F; Morita N; Kidani Y; Yajima T; Shimomura I; Watada H;
Diabetes Ther; 2022 Feb; 13(2):251-264. PubMed ID: 34962628
[TBL] [Abstract][Full Text] [Related]
17. Treatment satisfaction after commencement of insulin in Type 2 diabetes.
Wilson M; Moore MP; Lunt H
Diabetes Res Clin Pract; 2004 Dec; 66(3):263-7. PubMed ID: 15536023
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
[TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
Taki K; Koyanagi M; Nagaoka S; Shingaki T
Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
[TBL] [Abstract][Full Text] [Related]
20. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
